Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The first phase of the hospital with 225 beds built over 1.75 lakh square feet will be commissioned in the next 12 months
The companies will work with investigators to share the results with the scientific community
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
Subscribe To Our Newsletter & Stay Updated
